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R E V I E W
 
Toward an understanding of transfusion-related acute lung injury: 
statement of a consensus panel
 
Steven Kleinman, Tim Caulfield, Penny Chan, Robertson Davenport, Janice McFarland, 
Susan McPhedran, Maureen Meade, Douglas Morrison, Thomas Pinsent, Pierre Robillard, 
and Peter Slinger
 
ransfusion-related acute lung injury (TRALI) is
an uncommon clinical complication of alloge-
neic blood transfusion. Despite its increasing
recognition over the past 5 years, much about
TRALI remains poorly understood and controversial. Out-
standing issues include the lack of a universally accepted
case definition, uncertainty about incidence and patho-
genesis, and disagreement about both how to manage
 
donors who are associated with TRALI events and how to
reduce the risk of TRALI for recipients of blood products.
To address these issues, a Consensus Conference
was convened in Toronto, Canada, on April 1 and 2,
2004, entitled “Towards an Understanding of TRALI.” The
conference was sponsored by Canadian Blood Services
and Héma-Québec, with support from the International
Society of Blood Transfusion’s Biomedical Excellence for
Safer Transfusion (BEST) subcommittee. The format of
the conference was based on that used by the National
Institutes of Health and consisted of numerous expert
presentations covering issues relevant to the topic,
approximately 240 international attendees from a variety
of backgrounds, and a consensus panel of 11 members
covering a wide range of medical and other disciplines
(e.g., transfusion medicine, epidemiology, immunology,
anesthesiology, critical care medicine, and ethics as well
as a regular blood donor and a chronic transfusion
recipient). The Consensus Panel members, having first
reviewed summaries of the TRALI literature and Consen-
sus Panel procedures, convened immediately before the
conference to clarify objectives, principles, and roles.
Based on six questions posed by the Conference Steering
Committee, the Consensus Panel mandate was to
develop recommendations that could be applied both in
Canada and internationally.
This Consensus Panel report is based on the informa-
tion presented to the panelists during the conference, a
review of background literature and continued postcon-
ference discussion. Given the absence of systematic
reviews and randomized trials in this field, the Consensus
Panel recommendations are not graded according to cur-
rent evidence-based standards. In addition, no specific
evidence was presented to the Consensus Panel regarding
TRALI in neonates. Although TRALI among neonates is
not excluded from these recommendations, we acknowl-
edge the absence of data related to this specific popula-
tion. This statement addresses the six specific questions
posed by the conference steering committee. A publi-
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A variety of complications can be associated with
transfusion. How should TRALI be defined and what pro-
cesses should be implemented to develop objective cri-
teria for use in the classification of TRALI reactions?
 
An appropriate definition of TRALI could vary accord-
ing to the setting and purpose. Patient care clinicians need
an inclusive definition that will allow for a timely diagno-
sis in the face of patient comorbidities and the limitations
of available testing. For investigators evaluating interven-
tions for TRALI prevention or treatment, a firm diagnosis
based on objective criteria is highly desirable. This defini-
tion should necessarily be more exclusive. For surveil-
lance initiatives and epidemiologic studies, an exclusive
definition would underestimate incidence rates whereas
an overinclusive definition could overestimate incidence
and could also overwhelm efforts to evaluate implicated
donors, recipients, and transfused products.
Defining TRALI requires a balance of precision and
pragmatism. In any setting, TRALI cases might be classi-
fied as “mild,” “moderate,” or “severe” depending on
immediacy of onset, duration, and degree of patient dis-
ability. Classification along a spectrum of certainty could
lead to definitions of “possible,” “probable,” or “definite”
TRALI. Uncertainty will inevitably arise from the con-
founding effects of underlying respiratory or cardiac dis-
ease (e.g., congestive heart failure), coexisting risk factors
for acute lung injury (ALI; e.g., sepsis or shock), and other





In defining TRALI, the Consensus Panel decided on some
guiding principles. We sought portability, aiming to





 building on features of
TRALI where most experts can agree and incorporating





 avoiding distinct definitions for dif-
ferent subgroups and clinical settings.
TRALI is one of many subsets of ALI that share a com-
mon spectrum of clinical, physiologic, and radiologic
abnormalities. The American-European Consensus Con-
ference (AECC) definition of ALI, first described in 1992, is





 We adapted a previous recommen-
dation by a US National Heart, Lung, and Blood Institute
Working Group on TRALI that based its TRALI definition






The Consensus Panel recommends that TRALI be defined
as a new episode of ALI that occurs during or within
6 hours of a completed transfusion, which is not tempo-
rally related to a competing etiology for ALI (Table 1). The
diagnosis of TRALI is a clinical and radiographic diagnosis
and is not dependent on the results of laboratory tests or
any proposed pathophysiologic mechanisms. TRALI
should currently be considered a clinical syndrome rather
than a disease with a single etiology.
Consistent with the AECC definition for ALI, we have
defined TRALI by its timing, presence of hypoxemia, and
chest radiograph abnormalities and the absence of evi-
dence of circulatory overload, caused either by transfu-
sion or by  preexisting  cardiac  conditions.  Consistent
with pulmonary edema, chest radiograph abnormalities
should show bilateral infiltrates that may be patchy, dif-
fuse, homogeneous, or asymmetric and suggestive of alve-
olar or interstitial disease. Clinical evidence of circulatory
overload is defined as a pulmonary capillary wedge pres-
sure of 18 mmHg or greater, when a pulmonary arterial
catheter is present. Otherwise, in many situations where
this measurement is unavailable, clinicians must draw on
other signs (jugular venous pulsations, breath sounds, S3
gallop), symptoms (orthostatic dyspnea), and other data
(central venous pressure), to assist in their assessment of
circulatory overload. All of this is concordant with the




The ALI criteria for the definition of hypoxemia have
been expanded in the Consensus Panel definition of
TRALI. For clinical investigations we recommend defining
hypoxemia as a ratio of the partial pressure of oxygen to













 or as an oxygen saturation mea-
sured by pulse oximetry of less than 90 percent when a
 
















































 < 90% on room air
or other clinical evidence of hypoxemia
iii. Bilateral infiltrates on frontal chest radiograph
iv. No evidence of left atrial hypertension (i.e., circulatory 
overload)
b. No preexisting ALI before transfusion
c. During or within 6 hr of transfusion
d. No temporal relationship to an alternative risk factor for ALI
2. Possible TRALI
a. ALI
b. No preexisting ALI before transfusion
c. During or within 6 hr of transfusion
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patient is breathing room air. For the purpose of patient
care and surveillance studies, however, when pulse oxim-
etry measurements on room air may not be available,
other clinical evidence of hypoxemia may suffice.
There are numerous clinical conditions in which ALI








 related to both transfusion and at
least one other risk factor, the Consensus Panel recom-
mends the use of the term “possible TRALI” rather than
TRALI. The reasons for distinguishing TRALI from possible
TRALI (i.e., those cases without another temporally
related ALI risk factor from those cases with one) are mul-
tiple and include the uncertainty of the relationship of the
ALI to the transfusion event in possible TRALI, the need
to categorize such cases separately in surveillance systems
to permit accurate comparisons across systems, the abil-
ity to selectively target research protocols to TRALI or pos-
sible TRALI cases, and the possible adoption of differing
approaches to donor investigation in TRALI versus possi-
ble TRALI cases.
Importantly, the ALI risk factor of massive transfusion
is not considered to be a predisposing condition that
would require classification into possible TRALI and is not
listed in Table 2. Provided that the onset of the clinical
syndrome occurred within 6 hours of the last blood com-
ponent transfused, a massively transfused patient with
ALI symptoms would be considered a TRALI case, unless
the patient had one or more conditions listed in Table 2.
The distinction between TRALI and possible TRALI is
a subjective one, requiring a clinical assessment of the
possible influence of the alternate ALI risk factor. Because
of the subjectivity of such an assessment, the Consensus
Panel recognizes the potential for a given case to be clas-
sified differently by different institutions and researchers.
The Panel therefore urges that clear documentation con-
cerning the time course of symptom evolution be pro-
vided for those cases in which there is an alternate ALI risk
factor so that independent reviewers can also assess the
case. Factors that may provide suggestive evidence about
whether a possible TRALI case was indeed caused by
transfusion include the clinical course (TRALI is usually
less severe and resolves more quickly than ALI owing to
some other causes) and laboratory data that may be
obtained as part of a TRALI case workup (see below). Until
further knowledge is gained, however, the Panel suggests
that the term possible TRALI for such cases be maintained
for surveillance purposes. Detailed findings should be
reported at scientific conferences and in the literature so
that further scientific debate can ensue about when a case
can be moved from a designation of possible TRALI to
TRALI.
Table 3 outlines additional clinical signs and symp-
toms that have been frequently observed in TRALI cases
but which lack appropriate specificity for inclusion in the
definition of TRALI. These include dyspnea, tachycardia,
hypotension unresponsive to fluid administration, and
fever. Features of TRALI that are less clearly documented





This definition for TRALI has a number of strengths. Based
on an internationally accepted definition for ALI, and sim-
ilar to other definitions of TRALI, this definition addresses
the needs of varied settings and is relatively simple to
employ. Moreover, the Consensus Panel deliberately
avoided a classification scheme based on the pathophys-
iologic mechanisms of TRALI. Possible mild cases of
TRALI are excluded (i.e., cases with some pulmonary
symptoms that are not severe enough to meet the defini-
tion of TRALI) because no clear definition of such cases is
yet available and because their inclusion would compli-
cate tracking and comparison of TRALI cases in and
between surveillance systems.
Under the proposed definition, cases in which circu-
latory overload is present are excluded as TRALI cases. The
Panel recognizes that TRALI and circulatory overload can
coexist, however, as has been well documented for ALI




 It could be argued that such
cases should be classified as possible TRALI so that they
 




Direct lung injury Indirect lung injury
Aspiration Severe sepsis
Pneumonia Shock
Toxic inhalation Multiple trauma
Lung contusion Burn injury
Near drowning Acute pancreatitis
Cardiopulmonary bypass
Drug overdose
* The incidence of ALI varies considerably among these 
conditions and may be as high as 40 percent for intensive care 
unit-related cases of septic shock and aspiration or as low as 
2 percent for cases of cardiopulmonary bypass and intensive 
care unit-related drug overdose. The incidence and mortality of 





TABLE 3. Clinical symptoms and/or events observed 








Mechanical ventilation required to support oxygenation
Onset within 2 hr of transfusion
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are captured by surveillance systems and reported to
blood centers for further workup. Although the Panel con-
sidered this possibility, it decided to exclude such cases
from the possible TRALI category to be consistent with the
1994 AECC Consensus definition of ALI. Moreover, the
Panel recognized that when TRALI coexists with circula-
tory overload, the latter, more transient condition might
rapidly resolve with appropriate therapy (e.g., diuresis). At
that time, if the TRALI persists, a diagnosis of TRALI may
be made in hindsight and appropriately investigated. Of
course, mild and self-limited TRALI cases in the setting of
circulatory overload will be missed with this approach.
This definition also excludes a diagnosis of TRALI in
a patient with preexisting ALI who subsequently receives
a transfusion and whose ALI then worsens. Such cases are
excluded because of the absence of a method to establish
a causative link between the patient’s clinical course and
the transfusion.
The six-hour time limit for symptoms occurring fol-
lowing transfusion is consistent with most definitions that
are currently in use. Moreover, data presented at this con-
ference from the Serious Hazard of Transfusion (SHOT)
surveillance system in the UK indicate that such a time
limit will capture the large majority of TRALI cases. By use
of a 24-hour posttransfusion time frame, SHOT reported
that only 9 percent of suspected TRALI cases had symp-




Finally, this definition of TRALI carries those limita-
tions inherent to the AECC definition of ALI, most notably





 and the influence of positive end-












It is hoped that this proposed definition can be used as a
starting point to arrive at an international consensus def-
inition of TRALI and possible TRALI. Efforts are under way
in this regard. These definitions should be expected to
evolve as additional data are accumulated from improved
TRALI surveillance, epidemiologic studies, systematic
pathologic evaluations, and research into pathogenesis.
Question:
 
The magnitude of the risk of TRALI is unknown at
this time. What processes should be implemented to




The Panel agreed that the incidence of TRALI has not been
well established. As seen in Table 4, incidence rates in the
































































































































































































































































































































































































































































































































unit of red blood cells (RBCs).
The rates presented in Table 4 must be regarded with
caution for three major reasons. First, the definition used
for TRALI differed between studies. Some studies required
that antibodies to human neutrophil antigen (anti-HNA)
or anti-HLA antibodies be identified in the donor and that









Although most studies required signs and symptoms to













 Second, the meth-










 Third, the method of tabulating the
denominator data of products transfused also varied
across studies. Some studies used the number of products









 or the precise numbers of products
transfused in the institutions where the study took place.
(P. Robillard, personal communication).
Data on the severity and outcomes of TRALI are also
limited. A mortality rate of 5 to 10 percent is commonly




Higher and lower rates have also been reported, however.
 
METHODS TO IMPROVE KNOWLEDGE ON 
TRALI INCIDENCE
 
Accurate determination of incidence from various types
of blood components is important because component-
specific TRALI incidence may influence the decision to
adopt certain preventative measures. In the future, two
methods could be used to obtain data on TRALI incidence:
surveillance systems and incidence studies.
To improve our knowledge of the incidence of TRALI,
some prerequisites must be met. First, a standard defini-
tion of TRALI is needed so that comparison of cases across
studies is valid. Because of the potential for factors other
than transfusion to cause ALI in patients with severe clin-
ical illness, the Consensus Panel encourages the classifi-
cation of reactions into TRALI and possible TRALI and the
recording of such cases independently in surveillance sys-
tems. Second, good denominator data is needed to calcu-
late incidence rates. Theoretically, rates can be calculated
based either on the number of recipients or on the num-
ber of products transfused. The Panel believes that both
approaches to calculating TRALI incidence are useful and
encourage investigators to report TRALI incidence in both
ways when possible.
In the routine operational setting, it is usually easier
to obtain data on number of products transfused com-
pared to number of recipients transfused. If a product-
based denominator is used, it should be based on the
number of products by component type transfused (not
issued) in a given period of time in a given setting where
the TRALI cases are studied (hospital, hospital network,
province or state, country). The use of surrogate measure-
ments (e.g., products issued) might lead to false interna-
tional comparisons given that the transfusion practice
and the issuance of blood vary substantially between
countries. The use of products transfused, however, poses
a classification problem in patients receiving blood com-
ponents in that it may not always be possible to determine
which type of blood product caused the TRALI episode. If
recipient-based denominator data are collected, these
data will be maximally useful if patients can be tabulated
by the type of blood product received (e.g., RBCs vs. PLTs
vs. FFP). Because patients often receive more than one
type of blood product, however, it may be difficult to get




There are several surveillance systems for adverse trans-




Interesting data on TRALI have been gathered through
one of these systems, the SHOT system in the UK. Such
systems rely on passive reporting of adverse transfusion
reactions and are therefore subject to underreporting.
With respect to TRALI, reasons for underreporting include
the underrecognition of the syndrome by those who trans-
fuse the products as well as the lack of reporting of these
clinical events (and other adverse transfusion reactions)
to the transfusion service (and subsequently to the blood
center) for appropriate investigation.
The Consensus Panel recommends that the TRALI
definition provided in this statement be adopted by exist-
ing surveillance systems such as the Transfusion-Trans-
mitted Injury Surveillance System in Canada. The TRALI
definition should be given to all clinicians and nurses who
transfuse patients. Strategies for the appropriate dissemi-
nation of information on TRALI, such as active in-service
training for nurses and residents and publications in
prominent medical journals, should be adopted so that
the syndrome is better recognized and reported. In
addition,  transfusion  service  personnel  should  work
with nurses, anesthesiologists, and other physicians to
heighten awareness of TRALI at their institutions and to
improve surveillance.
 
Reporting of TRALI cases
 
Standardized reporting mechanisms should be adopted
within countries (and ideally internationally) to ensure
comparability of data. Denominator data on products
transfused should be collected by all surveillance systems.
Appropriate infrastructure should be provided to sur-
veillance systems to ensure that training is provided and
that adverse transfusion reactions, including TRALI, are
appropriately investigated and reported. Some institu-
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In some institutions with high transfusion volume, TRALI-
specific enhanced surveillance strategies in designated
services (like intensive care units) could be implemented.
This would require special training of the personnel work-
ing in that unit to recognize, report, and investigate all
suspected TRALI and possible TRALI cases. Ideally funds
should be made available to encourage the formation of
networks that would adopt such strategies. This mecha-
nism would allow more precise estimates of the incidence
of TRALI.
These sentinel sites could also provide valuable infor-
mation on the extent of underreporting of TRALI in gen-
eral surveillance systems. Another strategy to estimate
underreporting would be to conduct lookback investiga-
tions on recipients of donors implicated in a TRALI case.
This strategy is time-consuming and would best be con-




The best method to determine TRALI incidence accurately
would be to closely monitor all transfusions for the
appearance of clinical signs and symptoms related to
TRALI and to ensure that appropriate recipient investiga-
tions (e.g., chest X-rays, hypoxemia measurements) are
conducted to confirm the diagnosis. Given that TRALI is
of low frequency, this is clearly a research strategy that




What are the potential pathophysiologic mecha-
nisms leading to TRALI and what research questions
should be explored to investigate the mechanism(s)
leading to TRALI? 
 
There are two proposed pathophysiologic mecha-





 Clinical and experimental
observations support each of these mechanisms. In addi-
tion, several more speculative mechanisms have been
proposed, including direct injury to pulmonary endothe-
lium, immune complex formation with complement acti-
vation, and cytokine network activation. All proposed
mechanisms lead to a final common pathway of increased





The antibody hypothesis states that an antigen–anti-
body reaction triggers a series of events leading to TRALI.
Most often, the causative blood component contains anti-
bodies against recipient white blood cell (WBC) antigens.
More rarely (e.g., in approx. 10 percent of those cases that
occur through the antigen–antibody mechanism), the
antibody is present in the recipient and reacts with anti-
gens on transfused donor WBCs. Antibodies may be HLA
Class I or HLA Class II or directed against HNAs. It is pos-
sible that transfused HLA antibodies may directly activate
or injure pulmonary endothelial cells. In experimental
animal models, however, transfused antibodies work
through a different mechanism, by binding to circulating
WBCs, particularly neutrophils, causing cellular activa-
tion. Activated neutrophils, and possibly other WBCs,
lodge in pulmonary capillaries either through cellular
adhesive mechanisms or by physical trapping of WBC
agglutinates. Such activated neutrophils release vasoac-
tive substances, such as leukotrienes, or cytotoxic sub-
stances such as reactive oxygen metabolites. These
mediators cause pulmonary endothelial leakage or dam-
age with consequent pulmonary edema.
Evidence supporting the antibody hypothesis comes
from many TRALI cases in which HLA or HNA antibodies
have been demonstrated either in a transfused blood
component or in the serum of an implicated blood donor.
In many, but not all, such cases (approx. 40 in the litera-
ture), the corresponding antigen has been demonstrated
in the recipient (or a positive cross-match between donor





 In two lookback investigations, previous
donations from one donor with HLA and one donor with
HNA antibodies whose blood components were found to
have caused TRALI in an index recipient were found to





another lookback investigation reported entirely negative




 Although many HLA
Class I and Class II specificities have been associated with
TRALI, it is not clear from the present data whether there
are particular HLA specificities that are more likely to
cause TRALI. Case reports have associated each of the five





HNA-3a (formerly called anti-granulocyte 5b) has been
implicated in several severe cases of TRALI, including sev-
eral fatalities, indicating that this specificity may be par-




One randomized controlled clinical trial provides









 105) received 1 unit of multiparous
donor plasma (history of three or more pregnancies) and
1 unit of control plasma in random order separated by at
least a 4-hour interval. Notably, many patients had a risk
factor for ALI including pneumonia, sepsis, multiple









 ratio associated with transfusion









 98.3 mmHg) that was not observed with control
plasma. Five patients had clinical reactions, one of which
was evidently TRALI. The implicated unit in this case was
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lin G (IgG) neutrophil antibodies; however, a cross-match
with the recipient’s neutrophils was negative. This study
suggests that transfusion of plasma from multiparous
donors (presumably containing WBC antibodies) may
have a mild deleterious effect on pulmonary function in
the critically ill patient. Whether this effect is due to the
transfusion of antibodies and whether such plasma car-
ries an increased risk of causing clinical TRALI remains to
be proven in larger prospective studies.
Experimental evidence in support of the antibody



























resulted in rapid hypothermia, increase in lung water, and
hemoconcentration compared to animals injected with

















. Whole-animal spirometry indicated
that a pulmonary response similar to dyspnea accompa-
nied this reaction. Lung histology showed pulmonary
edema and intravascular neutrophil accumulation, simi-
lar to descriptions of TRALI in autopsy cases. Depletion of
neutrophils substantially reduced reactions caused by






A second experimental model supporting the anti-




 Rat lungs were ven-
tilated, perfused with physiologic buffer, and excised. In
this method, ventilation and perfusion pressures were
controlled. Human neutrophils were introduced into the
perfusion circuit and subsequently monoclonal anti-
HNA-2a or control antibody was added to the perfusate.
Capillary permeability and lung weight increased after




70% HNA-2a-positive) and anti-
HNA-2a, but not with control antibody. The response was
blunted when less than 30 percent HNA-2a-positive
neutrophils were used. The onset of these events was
accelerated by the addition of the neutrophil activator
formyl-methionyl-leucyl-phenylalanine. Lung histology
showed pulmonary edema and neutrophil accumulation.
Evidence that the antibody hypothesis may not be
sufficient to explain all cases of TRALI comes from several
sets of observations. All reported case series include cases
in which neither HLA nor HNA antibodies could be dem-
onstrated in any donor or in the recipient. WBC antibod-
ies, particularly HLA Class I antibodies, are far more
common in transfused blood components than is TRALI
in recipients of these components. Lookback studies of
implicated donors (e.g., donors who had a detectable anti-
body to an antigen specificity present in the TRALI
patient) have found fewer cases of TRALI than would be





 In summary, not all cases of TRALI are
associated with donor HLA or HNA antibodies and not all
transfusions of components from donors with HLA or
HNA antibodies cause TRALI.
The two-event hypothesis for TRALI (also termed the
neutrophil priming hypothesis) states that TRALI is the




 The first event causes
neutrophils to be primed, but not activated (first hit), and
the second event causes activation of primed neutrophils
(second hit). In the clinical setting, one of the events is
caused by the patient’s underlying clinical condition
(infection, surgery, inflammation) whereas the other event





phil priming or activation may occur with the infusion of
substances in the plasma of the transfused product; these
may be antibodies (via antigen–antibody reactions) or
other biologically active substances (e.g., biologically
active lipids) that accumulate in the blood product.
Support for the neutrophil priming hypothesis comes
from the investigation of TRALI cases in which WBC anti-
bodies could not be demonstrated. The largest series of





concentrates or RBCs were judged to be the causative
component in all but one of these cases. Of 28 cases inves-
tigated for antibodies, HLA or HNA antibodies were found
in only 7 (7 positive donors in 104 tested donors). Elevated
neutrophil priming activity was detected in implicated
PLT concentrates when assayed by measurement of
superoxide anion production of normal neutrophils. Ele-
vated neutrophil priming activity was also found in the
postreaction plasma samples of TRALI patients compared




 34), but no such dif-














 6) localized the neutrophil
priming activity to lysophosphatidylcholines (lyso-PCs)
and neutral lipids.
Experimental evidence in support of the neutrophil
priming hypothesis comes from two models. In an ex vivo
model, rats were treated with lipopolysaccharide (LPS) or





 After LPS treatment and perfusion with
the supernatant of 42-day stored RBCs, there was
increased pulmonary artery pressure and lung edema.
Histology showed edema and intravascular neutrophil
accumulation. These did not occur with saline treatment
or with perfusion with supernatant from fresh RBCs. Lipid
extracts of 42-day stored RBCs or purified lyso-PCs also




 Treatment of ani-
mals with a calcium channel blocker or a PLT-activating
factor receptor blocker prevented lung injury. More
recently, similar results have been obtained with 5-day




A second experimental model involved the culture
of human pulmonary microvascular endothelial cells




HMVECs were activated with LPS and exposed to neutro-
phils before addition of neutrophil-activating lyso-PC.
Killing of HMVECs was observed and was dependent on
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LPS treatment and the dose of lyso-PC. Blocking antibod-
ies to the endothelial cell adhesion molecule ICAM-1 or
the neutrophil receptor CD18 inhibited HMVEC killing.
HMVEC killing could also be reduced by the addition of




, and interleukin (IL)-8. This model suggested that TRALI
can result from a sequence of events involving endothelial
activation (first hit), adhesion of neutrophils, and activa-
tion of adherent neutrophils (second hit).
The observed neutrophil dependence of experimental
TRALI models has led to the hypothesis that neutrophil
activation is a required intermediate event in the causation
of ALI. Evidence that neutrophil priming and/or activation
may not occur in all TRALI cases, however, comes from
several sources. First, many cases of TRALI have occurred
following the transfusion of FFP, in which elevated neutro-





there are case reports of TRALI in severely neutropenic





son, personal communication). Third, a report of unilateral
TRALI occurring in a transplanted lung suggests that
endothelial cell HLA antigens, not neutrophil antigens, can




 Finally, it is
unknown whether TRALI cases caused by HLA Class II





 HLA Class II antigens are not expressed on resting
neutrophils and there is controversy over whether such
antigens are expressed on cytokine-activated neutrophils.
Other possible mechanisms for TRALI have been sug-
gested, but these are not supported by clinical and experi-
mental evidence. Monocyte antibodies
and/or monocyte activation have been





ines or other yet to be identified biologic
response modifiers that are present in
blood components and which may
increase with blood component storage
may directly or indirectly activate or
injure pulmonary endothelium. One
possible candidate for this latter mecha-
nism is IL-8, which has been shown to
directly increase permeability of cul-





summary of our current understanding
of TRALI pathogenesis is presented in
Fig. 1.
The existing theories and evidence
on the pathophysiology of TRALI leave a




What options are available for
managing donors implicated in TRALI
reactions?
 
APPROACHES TO DONOR MANAGEMENT
 
The Panel was presented with multiple approaches to
donor management by the conference speakers. The
Panel notes that donor management in TRALI is a com-
plex issue with many decision points depending on the
extent of the workup that is completed and the findings
that are generated. Because of these factors, the Panel was
not able to reach consensus on all aspects of this question.
Instead, the Panel has attempted to delineate the issues
logically and to indicate some of the critical decision
points.





TRALI reaction if one of his or her blood components was
transfused during the 6 hours preceding the first clinical
manifestation of TRALI. The Panel has defined an associ-




 in TRALI if antibodies to an HLA
Class I or II antigen HNA with specificity against an anti-
gen present on the recipient’s WBCs are detected.
The Panel discussed several approaches to donor
management. The first approach was to take a uniform
action for all donors associated with a case without per-
forming any laboratory testing to identify an implicated
donor. Possible actions would include deferring these
donors from all future donation or restricting them to
whole-blood donation with washed RBCs as their only
allowable transfusable component. Another possible
action would be to allow such associated donors to con-
tinue to donate but to place a flag in the donor record so






Postulated pathophysiologic mechanisms of TRALI. The lightface arrows repre-
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ated with another TRALI case. It was noted that there were
two problems with this donor record flagging approach.
The first problem was that this might result in a subse-
quent case of TRALI that might have been preventable if
more stringent donor management approach had been
adopted. The second problem is based on a possible inter-
pretation of Canadian informed consent requirements
for recipients. In Canada, the informed consent process
requires health-care providers to tell a patient about any-





 One possible interpretation of this
requirement is that a recipient of a blood product from a
“flagged” donor must be informed of the fact that the
donor has been associated with a previous TRALI event.
From a public trust perspective, this interpretation of con-
sent law seems appropriate. Thus, if this interpretation is
correct, then donor flagging would not be practical to
implement.
With regard to TRALI cases, the Consensus Panel did
not endorse either variation of the above approach. The
Panel favored a more targeted approach to donor manage-




donors to identify the implicated donor whose compo-





 donor is to prevent the transfu-
sion of future plasma containing donations from this
donor, thereby possibly preventing TRALI in future recip-
ients, and to avoid the unnecessary deferral of associated
donors who are not implicated.
In the past, there have been at least two other reasons
to perform laboratory workups in TRALI cases. First, some
investigators have required positive serologic findings to
designate a case as TRALI. Based on the Panel’s proposed
definition of TRALI, such positive laboratory findings are
not necessary to make the diagnosis. Second, donor, prod-
uct, and recipient laboratory testing have been important
in elucidating the pathophysiology of TRALI. The Panel
sees this as a highly desirable research goal, but not
directly related to the question of donor management.
With regard to possible TRALI cases, the Consensus
Panel believes that each blood collecting agency must
decide if laboratory case investigation and donor manage-
ment will be handled in the same fashion as for TRALI
cases or if less stringent or otherwise different protocols
should be adopted. The Panel notes that from a research
rather than an operational perspective, it would be impor-
tant to perform such investigations.
A flow chart detailing the steps involved in deciding
to initiate and in performing a laboratory workup is pre-










     Obtain recipient specimen from hospital:
                 Type for HLA Class I and Class II antigens (or procure information from patient record) and possibly for neutrophil
                 antigens and/or use for performance of cross-match with donor specimens
     Obtain donor specimens either from blood component residual volume or from recall of donors (all donors or sequential
     testing algorithm)
                 Test donor specimens for HLA Class I, HLA Class II, and HNA antibodies
                           If HLA antibody identified, type for specificity




Case reported from transfusion service to blood center
Adequate clinical information?
Classify case into one of
three categories
Request further information
and/or no action taken
No further action takenLab investigation at
discretion of collection agency
Perform lab investigation
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Prerequisites for performing a laboratory workup
 
A laboratory workup of a TRALI case is expensive and may
require considerable effort by the blood center to contact
associated blood donors to obtain necessary blood speci-
mens. Furthermore, donors may experience anxiety and/
or concern that their blood donation may have resulted in
harm to a recipient. For these reasons, the Panel has con-
cluded that before a blood center initiates a TRALI donor
case investigation, the transfusing institution has the obli-
gation of providing complete information on the TRALI
case to the blood center. Information to be provided
includes sufficient clinical data to confirm the TRALI diag-
nosis and to exclude other causes of ALI as well as the
results of any laboratory tests performed to rule out other
transfusion reactions (e.g., acute hemolytic transfusion
reactions, sepsis). Data as to the storage age of the trans-
fused components are also important for evaluating the
neutrophil priming hypothesis of TRALI pathogenesis.
 
Antibody and antigen testing
 
A complete case workup for the antibody etiology of
TRALI requires both donor and recipient specimens.
Donor samples should be tested for HLA Class I and II
antibodies and for HNA-specific antibodies. There are
now enough TRALI cases in which donors with HLA Class
II antibodies have been implicated to make HLA Class II
antibody testing a mandatory part of the workup.27 If ini-
tial HLA Class I or II reactivity is identified, testing for the
specificity of the HLA antibodies is required. If HNA anti-
bodies are detected, ideally their specificity should also be
determined. The Consensus Panel is aware, however, that
the laboratory capability for determining HNA antibody
specificity is more limited than for HLA antibodies.
There are two possible sources of donor specimens:
residual volume from transfused components or fresh
specimens obtained from recalling donors. It is likely that
residual volume will not be available for all associated
components. Furthermore, the Panel was not provided
with any information to assess the adequacy of residual
volume specimens for further antibody testing. (One
speaker noted that archived samples have been associated
with a high false-positive rate in neutrophil serology.) The
Panel concludes that recall of donors will be necessary to
complete many case evaluations.
A donor can be regarded as implicated in TRALI only
if found to have antibodies to an HLA Class I or II antigen
or HNA and either that antibody has specificity for an
antigen present on the recipient’s WBCs or there is a pos-
itive reaction demonstrated between donor serum and
recipient WBCs (i.e., a positive cross-match). Therefore, a
workup either requires the determination of the HLA type
of the recipient, the neutrophil type of the recipient, or a
cross-match between donor serum and patient cells. A
recipient blood specimen containing adequate cells for
cross-matching and/or for HLA and/or neutrophil typing
should be obtained, as soon as possible after the TRALI
episode by the transfusing facility and sent to the blood
center. In some cases, depending on the patient’s diagno-
sis, recipient HLA typing data may be available in hospital
records.
Owing to the expense of donor testing and the logis-
tics of recontacting donors, the question arises as to
whether all donors associated with a TRALI case need to
be investigated. The Panel notes that several speakers pre-
sented protocols for testing donors sequentially and dis-
continuing donor testing once a single implicated donor
had been identified.1 Examples of such protocols include
beginning testing with donors whose components were
administered closest to the onset of TRALI; donors of
plasma, PLTs, cryoprecipitate, and RBCs, in that order;
and multiparous female donors, other female donors, and
then male donors. The Consensus Panel agreed that either
a simultaneous investigation of all donors or a sequential
approach to donor investigations would be reasonable
but was not able to evaluate which of the sequential test-
ing approaches would be preferable.
The specific approach to investigating donors could
vary depending on the number of donors associated with
a given case. The Panel, however, saw no reason to impose
an arbitrary upper limit on the number of donors who
should be tested in a TRALI case. Because laboratory
investigation is confined to donors of components trans-
fused in the 6 hours preceding TRALI onset, it should be
rare that the number of donors in a given case will be
unmanageable, even if it is necessary to investigate all
associated donors. Patients receiving extraordinarily large
numbers of components may have other temporally asso-
ciated risk factors for ALI that preclude a specific diagno-
sis of TRALI and obviate the need to investigate the
associated donors.
For detection of HLA antibodies, some techniques are
more sensitive than others (e.g., Flow PRA is more sensi-
tive than microlymphocytotoxicity).1,26 For detection of
HNA antibodies, the Panel noted that several speakers
reported weak and/or nonspecific reactivity, the signifi-
cance of which has not been defined.1 Antibody detection
methods should be standardized and sensitive, with
screening panels selected to provide appropriate ethnic
diversity and the ability to detect all clinically relevant
antibodies.
Some cases of TRALI have been caused by antibodies
in the recipient interacting with antigens on the donor
cells. Most, if not all, of these cases occurred after transfu-
sion of nonleukoreduced units.10 Because of the low fre-
quency of this cause of TRALI, the Panel considers this
additional workup to be unnecessary for the purposes of
donor management.
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Neutrophil priming activity
One set of investigators has identified increased neutro-
phil priming activity in stored blood components as an
etiologic factor in some cases of TRALI.6,12 This activity is
assessed by adding plasma or serum (from a stored blood
component or the recipient) to an assay system contain-
ing fresh neutrophils from volunteer donors and measur-
ing the neutrophil respiratory burst after stimulation with
formyl-methionyl-leucyl-phenylalanine.
There are two possible sample sources for measuring
neutrophil priming activity in TRALI cases. One approach
is to measure this activity in pre- and posttransfusion
samples from TRALI patients and to thereby determine
whether such activity has increased after a TRALI event. A
second approach is to measure neutrophil priming activ-
ity in the residual volume of associated transfused com-
ponents. Until neutrophil priming activity assays are more
widely available and standardized (and accompanied by
reference ranges for stored components), the Panel does
not recommend such testing as part of a routine TRALI
case investigation. The Panel encourages such workups in
a research setting.
DONOR MANAGEMENT
A donor is implicated in TRALI if found to have HLA Class
I, HLA Class II, or HNA antibodies with a specificity
directed against an antigen present on the recipient’s
WBCs or demonstrated by a positive cross-match. An
implicated donor should either be permanently deferred
from donation or have the plasma from future whole-
blood donations diverted for fractionation, have no PLTs
manufactured from the donation, have their RBCs washed
(or frozen and deglycerolized) before transfusion, and be
permanently deferred from future apheresis donation.
This policy recommendation is based on documented
instances in which donors with antibodies have been
implicated in TRALI reactions in multiple recipients.14,15
Although the evidence for this phenomenon is strongest
for anti-HNA-3a (i.e., anti-granulocyte 5b), the Consensus
Panel was of the opinion that a precautionary approach
dictates taking this deferral action for any implicated
donor, regardless of antibody specificity. This policy errs
on the side of recipient safety in that it may lead to the
deferral of some safe donors with common specificity
antibodies that either may not have been the cause of
TRALI in the recipient or, even if causal, might not cause
TRALI in future recipients.
Multiple scenarios, as described in Table 5, may be
encountered in performing a TRALI donor case investiga-
tion. Important variables that may influence donor man-
agement decisions include:
• Whether a recipient specimen has been obtained;
• Whether an implicated donor is identified; and
• In the absence of an implicated donor, whether spec-
imens are obtained from all associated donors.
In the absence of a recipient sample (or of a known
HLA type), it is not possible to identify an implicated








Recipient specimen antigen 
testing or cross-matching result* 
Result obtained Result not obtained 
All donors tested
Some donors not 
tested All donors tested
Some donors not
tested







TBD§¶ TBD¶ NA NA
Antibody-negative
donors
Continue to donate Continue to donate NA NA
Nontested donors NA Continue to donate NA NA
No implicated donor found Other antibody-positive
donors
TBD¶ TBD¶ TBD¶ TBD¶
Antibody-negative
donors
Continue to donate Continue to donate Continue to donate Continue to donate
Nontested donors NA TBD NA TBD
* Recipient specimen may be typed (HLA and/or HNA) by a blood center or hospital or may be available from hospital records. Alternatively 
or in addition, cells from the recipient may be available for cross-matching with donor sera.
‡ NA = not applicable.
† The action is to permanently defer the donor from donation or to divert plasma from future whole-blood donations to fractionation, wash RBCs 
before transfusion, and defer from apheresis donation.
§ TBD = to be determined by those responsible for the blood supply in a given regional or national jurisdiction.
¶ The Consensus Panel believes that the decision with regard to these antibody-positive, nonimplicated donors needs to be determined by 
each jurisdiction. The Panel reached consensus that if a donor in this category had an HNA antibody of defined specificity, that donor should 
be managed in the same fashion as an implicated donor (see above). With regard to HLA antibodies, the majority of the Panel felt such 
donors should be allowed to continue to donate; the minority opinion was that they should be managed as an implicated donor.
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donor by the Consensus Panel definition. In such cases,
the decision to perform any donor antibody testing
should logically be contingent on whether the institution’s
donor management policy would result in different out-
comes for donors with or without detectable antibodies.
Donors with HLA or HNA antibodies not specific to a
recipient antigen may be identified in cases in which
another donor has been found to be an implicated donor
or in cases in which no implicated donor is identified. The
Panel was unable to reach full consensus as to proper
management of such antibody-positive donors and
believes that this decision should be made by those
responsible for the blood supply in regional or national
jurisdictions. The deliberations of the Consensus Panel,
however, may be helpful to guide policy makers. First, the
Panel reached consensus that deferral action should be
taken for nonimplicated antibody-positive donors with
anti-HNA antibodies with identified specificity. This rec-
ommendation is based on the positive lookback studies
and mortality data associated with anti-HNA-3a, which
the Panel generalized to other well-identified anti-HNA
specificities.14,17,18 This recommendation does not apply to
anti-HNA antibodies that are nonspecific; the Consensus
Panel emphasizes that the significance of such antibodies
in TRALI is unknown and therefore should not be the basis
of a deferral action in nonimplicated donors.
The policy with regard to nonimplicated donors with
HLA antibodies was less clear because such antibodies
may be found in approximately 10 to 20 percent of female
donors and therefore could occur as a chance finding in a
donor to a TRALI case.1,13,26 For this reason, the Panel’s
majority opinion was that no action be taken on these
donors (i.e., they be allowed to continue to donate), espe-
cially if the donor was ruled out as an implicated donor
based on recipient antigen typing or donor–recipient
cross-matching. The minority opinion within the Panel,
however, was that the presence of an HLA antibody should
lead to deferral action based on the premise that such a
donor could potentially trigger TRALI in a future recipient
with a corresponding antigen. A third potential option was
to allow such donors to continue to donate but to flag their
donor record. The Consensus Panel rejected this option
based on the ethical and legal concerns previously
discussed.
The Panel agreed that donors with negative tests for
HLA and/or HNA antibodies may continue to donate
whether or not the TRALI case investigation identified an
implicated donor. To the Panel’s knowledge, there is no
evidence that such antibody-negative, TRALI-associated
donors pose any additional risk to future transfusion
recipients.
Question:
Is there sufficient evidence, at this time, to recom-
mend that any laboratory screening tests and/or other
deferral measures be implemented to exclude donors to
reduce the risk of TRALI?
There are several sources of data indicating that
TRALI is currently one of the leading causes of transfusion
mortality in developed countries. As reported at this con-
ference, TRALI appears to have been the leading cause of
transfusion mortality from 2001 to 2003 in the US.1,30
Based on reports to the FDA, there was an average of 16
fatal TRALI cases per year. In the UK, the SHOT program
has attributed 24 deaths to TRALI over 7 years.7 In Canada
(excluding Quebec), 13 deaths were reported in nearly
3 years and two additional deaths over 4 years were
reported by the Quebec hemovigilance system.1,31 Fur-
thermore, owing to underrecognition and underreporting
of TRALI, these data almost certainly underestimate the
extent of severe morbidity from TRALI.
Based on the available scientific evidence, the Con-
sensus Panel first noted that there are no laboratory
screening tests and/or other deferral measures that can be
totally effective or specific for preventing TRALI. Because
TRALI is a serious risk of transfusion, however, the Panel
believes that a precautionary approach should be taken to
policy development regarding decreasing the risk of
TRALI. That is, in the absence of complete information,
preventive measures should be taken even if the effective-
ness of the measures is not fully known. There must be a
valid rationale, however, for the specifically recommended
measure(s) and there must be a balancing of the risks of
not implementing the measures (e.g., the occurrence of
morbidity associated with TRALI cases) against the risks
of implementing them (e.g., the impact on blood availabil-
ity and donor loss). Such a precautionary approach is
extremely important in the context of blood safety, where
delays or perceived reluctance to deal with past health
risks have affected public trust and, in some jurisdictions,
have threatened the integrity of the blood system.
The Panel noted that the two main hypotheses on
the cause of TRALI lead to very different strategies for
prevention. Although the antibody hypothesis dictates
that excluding plasma from specific donors with patho-
genic antibodies will prevent TRALI in recipients, the
neutrophil priming hypothesis suggests that, indepen-
dent of donor characteristics, providing reduced storage
age or washed cellular blood products will prevent TRALI.
Because there is evidence to support both mechanisms, it
is likely that adopting a specific prevention strategy tar-
geted at one of these mechanisms will be only partially
effective. In addition, strategies directed against either
mechanism are nonspecific and will reduce available
blood components by excluding many safe donors (anti-
body hypothesis) or excluding safe products (neutrophil
priming hypothesis).
The Panel agreed that there was currently one general
strategy that should be adopted to reduce TRALI risk via
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both mechanisms. That strategy is to encourage adher-
ence to current guidelines for blood component utiliza-
tion to minimize inappropriate use. This will reduce the
risk of all transfusion-related adverse reactions. The Panel
also recommended the deferral of donors positively impli-
cated in a TRALI reaction (or restricting their transfusable
components to washed RBCs only) because this would
decrease TRALI risk by the antigen–antibody mechanism.
The Panel considered other proposals that could
potentially decrease the risk of TRALI owing to the anti-
gen–antibody mechanism. These proposals are based on
restricting donations from certain groups of donors who
are known to have higher rates of WBC antibodies, either
owing to demographic characteristics (sex, parity) or
through detection by previous testing.1 Restrictions
imposed on such donors could include: deferring donors
from any type of blood donation; permitting whole-blood
donation but diverting the use of plasma from FFP pro-
duction to fractionation; deferring donors from the dona-
tion of components that have high plasma volume (e.g.,
apheresis plasma or apheresis PLTs); or a combination of
the latter two approaches. Application of these strategies
could be considered for any of the following groups of
donors, listed in decreasing order of the number of donors
affected:
• All female donors and all transfused male donors;
• All female donors;
• All previously pregnant female donors;
• All multiparous female donors
• Donors with previously demonstrated WBC antibod-
ies (either by history or through screening programs
initiated for this purpose).
Applying restrictions to any of these groups is non-
specific and would result in a loss of usable, safe blood
components (i.e., components that will not cause TRALI)
from large numbers of donors. The Panel noted that, in
many jurisdictions, it may be unrealistic to defer any of
the above groups of donors from whole-blood donation
owing to the potential large impact of such a policy on
blood availability. The Panel, however, was not provided
with enough information to assess the impact on compo-
nent availability or on donor behavior of deferring donors
from apheresis donation or diverting plasma from FFP
production. Accordingly, the Panel believes that more
detailed assessments of the impact of these strategies ver-
sus their potential risk reduction need to be undertaken
by those responsible for the blood supply in a given juris-
diction. These assessments should include:
• Estimates of the degree of risk reduction to be
achieved by the strategy. This will be dependent on an
analysis of national (or local) TRALI incidence data,
TRALI morbidity and mortality data, association of
TRALI with blood component type, and evaluation of
whether cases were caused by the antigen–antibody
mechanism.
• Impact of the strategy on the number and availability
of donors and the supply of blood products.
• Impact on the donor population, including willing-
ness to continue donating.
• Impact on the fractionated plasma pool owing to
changed characteristics of input plasma (i.e., a larger
percentage of plasma from female donors).
• The logistics of identifying donors in any of the des-
ignated groups. For example, identifying previously
transfused males or multiparous females would likely
require an additional donor screening question at
each donation.
• The feasibility of mass screening for HLA (or HNA)
antibodies.
• Financial costs and cost-effectiveness of implemen-
tation of any of the proposed strategies.
Such assessments will define whether the benefit of
restricting donations or diverting plasma from any of the
groups of donors mentioned outweighs the risk to the
safety and availability of the blood supply. Different con-
clusions may be reached in different jurisdictions. For
example, the Panel notes that a risk assessment carried
out in the UK resulted in the decision to divert plasma
from female donors away from FFP production.7 The UK
situation with regard to use of plasma, however, is rela-
tively unique in that UK plasma is not sent for fraction-
ation because of variant Creutzfeldt-Jakob disease safety
concerns.
In addition to the strategies discussed above, the
Panel was presented with three other prospective preven-
tion strategies.
1. Use of “fresher” blood when transfusing patients at
risk for TRALI. This strategy could be helpful in pre-
venting cases attributed to the “two-event” mecha-
nism if initial observations that neutrophil-activating
substances  accumulate  in  greater  concentrations
in blood components with increased storage time are
confirmed. The Panel notes there is currently no
consensus of which patient groups are at risk for
TRALI.
2. Use of solvent/detergent plasma (if licensed and
available) in place of FFP. This suggested strategy was
based on the antigen–antibody mechanism and the
fact that the pooling process would lower the titer of
any pathogenic antibody and thereby potentially pro-
tect against TRALI. Surveillance data are not currently
adequate to evaluate this hypothesis.
3. Use of PLT storage solutions if any become licensed.
The value of this strategy is theoretically based on
either the antigen–antibody mechanism (e.g., reduc-
ing the concentration of antibody by replacing
plasma volume with additive solution) or the two-
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event model (reducing the accumulation of neutro-
phil priming substances).
The Panel felt that there were insufficient data for the
potential benefits of any of these additional proposed
strategies to be determined at the present time but has
listed these suggestions to promote future research.
Question:
What further information and systematic research
is necessary to better evaluate the issues of the epidemi-
ology and pathophysiology of TRALI, to reduce the risk
to transfusion recipients?
The current understanding of the epidemiology, mag-
nitude of risk, and pathophysiology of TRALI has been
limited by several factors. These include the lack of a uni-
form definition of TRALI, the presence of other possible
confounding causes of pulmonary edema in the same
patients who develop TRALI, and the lack of well-designed
prospective observational or randomized, controlled clin-
ical trials of adverse transfusion events.
The international representation at this consensus
conference indicates the worldwide motivation to reduce
the risk of TRALI among transfusion recipients. Reducing
risk must start with a concerted effort to better under-
stand the epidemiology of TRALI. Knowledge of what con-
stitutes a high-risk donor, blood product, and recipient
should allow clinicians and researchers to better under-
stand pathophysiologic mechanisms and to evaluate pre-
ventive actions and/or to appropriately target their efforts
at risk reduction.
The Panel recommends a focused plan for epidemio-
logic research. First, a uniform, internationally accepted
definition of TRALI is required to make possible reliable
comparisons between different studies and expedite all
research in this area. Second, the Panel recommends that
resources for systematic epidemiologic research be tar-
geted to multiple high-volume transfusion centers or
regional networks of collaborating hospitals with varied
recipient populations. Third, such centers need to
develop an infrastructure that will allow systematic sur-
veillance for all TRALI reactions. To the extent possible,
there should be standardized specimen and data collec-
tion related to recipients, their associated donors, and
transfused blood products. Rigorous postmortem patho-
logic assessments should be obtained for those patients
who die from TRALI.
Research studies should be performed both on TRALI
cases and on possible TRALI cases as an additional group
using our proposed definitions. Initial research on TRALI
cases should be targeted to determining the incidence of
TRALI associated with the various types of blood compo-
nents, the severity of outcomes, and the mortality rate.
Research  should  also  focus  on  the  possible  predictors
of TRALI reactions among donors, blood products, and
transfusion recipients. Studies should investigate the
genetic, demographic, and clinical factors in the recipient
that predispose to, or afford protection against, TRALI. In
this context, additional lookback investigations of recipi-
ents of previous products from an implicated donor may
prove useful. In the future, once risk factors are better
defined, further epidemiologic research should include
comparisons with control groups that may be matched by
donor characteristics, blood products, or recipient char-
acteristics to further define independent risk factors that
contribute to TRALI occurrence. Research on possible
TRALI cases should focus on some of the same issues as
well as on developing criteria that can determine whether
a possible TRALI case is due to transfusion or is the result
of other ALI risk factors.
There are several additional clinical and epidemio-
logic questions that can be addressed. Because the neu-
trophil is thought to play a critical role in most models of
pathogenesis, cases of TRALI in severely neutropenic
patients should be subjected to extensive study. The pos-
sibility of mild cases of TRALI (e.g., cases not fitting the
proposed definition) has been suggested and this should
be further investigated. The mechanisms of fever and
hypotension in TRALI have not been elucidated.
Meanwhile, the Panel also recommends that blood
collection agencies develop their capabilities, share their
expertise, and possibly, pool resources to allow for all
cases of TRALI, particularly those occurring at centers
involved in epidemiologic studies, to be fully investi-
gated. These research investigations should, ideally,
always include tests for antigen–antibody concordance,
as well as neutrophil priming activity. In the context of
such investigations, we recommend that standardized
and optimized laboratory methods be developed with the
aim of being able to more reliably compare findings from
one laboratory to another. For example, the characteris-
tics of “implicated” antibodies, including immunoglobu-
lin class, subclass, and titer, should be defined and
compared to those of antibodies that are transfused to
patients who suffer no adverse event. With regard to the
neutrophil priming model, investigators should seek
direct evidence for neutrophil priming, neutrophil activa-
tion, and pulmonary endothelial injury, and address the
issue of whether neutrophils are necessary for tissue
damage to occur.
In the meantime, basic research on TRALI pathogen-
esis would be enhanced by the development of in vitro
systems in which evidence of cellular activation and/or
damage can be documented. This applies to both the anti-
gen–antibody and the neutrophil priming models. Both
clinical and laboratory studies should be undertaken to
define antibody specificities (including immunoglobulin
class, subclass, or interaction with complement) and anti-
body titers carrying the greatest risk of TRALI. If patho-
genic WBC antibodies are identified, studies should
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explore their neutrophil priming activity and/or other
mechanisms (e.g., complement fixation, cytokine release)
that could lead to pulmonary damage.
Further investigations of the neutrophil priming
hypothesis, including confirmation of findings by inde-
pendent laboratories, should be encouraged. Studies are
necessary to ascertain the neutrophil priming activity of
large numbers of blood components in different anticoag-
ulants at varied storage ages as well as baseline determi-
nations of such activity in various patient populations.
The correlation between lyso-PC concentration, in vitro
neutrophil priming activity, and clinically recognizable
TRALI should be investigated.
Further development of animal models will be essen-
tial to a better understanding of TRALI. Development of a
standardized model that could be used to investigate mul-
tiple pathophysiologic mechanisms with the same exper-
imental system should be encouraged. Based on the above
discussion, the Panel has categorized some suggested
research questions into various categories as presented in
Table 6.
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